Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

Saliency-based score highlighted biologically meaningful regions, especially the optic nerve head and retinal vasculature.

The novel topical gel, designed to clear mutant keratin aggregates and restore intermediate filament network integrity via autophagy, is undergoing evaluation in the phase 2 TAMES-02 trial.

The FDA wants to remove a limitation stating that the therapy's safety and effectiveness have not been established in men with age-related low testosterone ...

Rifapentine is a cyclopentyl rifamycin antimycobacterial agent indicated for the treatment of active pulmonary tuberculosis and late tuberculosis infection.

HealthDay News — Clover Hill Dairy is recalling all of its brand cheese over possible Listeria contamination tied to a ...

Transitioning from accelerated to traditional status, the FDA's decision expands eligibility for the first solid-tumor engineered T cell therapy to include adolescents aged 12 and older.

In patients with 1 prior line of systemic therapy, the IB6-directed ADC showed favorable trends in both overall survival and progression free survival vs docetaxel.

Living guideline presents pharmacologic treatments that are recommended with lifestyle modifications for weight management.

DT120 ODT significantly improved MADRS scores at week 6 compared with placebo (-13.3 vs. -5.2; P .0001). Topline data were announced from a phase 3 trial evaluating DT120 (lysergide) orally ...

Supported by the phase 3 NIMBLE trial, the novel siRNA met its primary endpoint, demonstrating significant 24-week improvements in MG-ADL scores.